Sean Hamlett, DO
Endocrinology, Diabetes & Metabolism · Columbia, MONPI 1255379970
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AstraZeneca at 56.4% of the total. Reporting peaked in 2019 at $4,317 and has fallen 63.1% since, to $1,594 in 2025.
Across 99 payments — averaging $64.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Tandem Diabetes Care, Inc.$803
- Medtronic$349
- Novo Nordisk$280
- Corcept Therapeutics$225
- Recordati_rare_diseases_inc.$154
- plus $954 from 17 others
What the payments were for
- Speaking & faculty fees$3,45054%
- Grants$1803%
- Travel & lodging$61610%
- Food & beverage$2,09133%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 7 | $3,573 |
| Tandem Diabetes Care, Inc. | 5 | $803 |
| Medtronic(2 entities) | 6 | $349 |
| Novo Nordisk | 17 | $280 |
| Corcept Therapeutics | 10 | $225 |
| Recordati_rare_diseases_inc. | 4 | $154 |
| Amgen | 8 | $148 |
| Radius Health, Inc. | 11 | $143 |
| Dexcom, Inc. | 7 | $122 |
| Ascendis Pharma Endocrinology Inc | 3 | $83 |
| AbbVie | 4 | $75 |
| Xeris Pharmaceuticals, Inc. | 3 | $67 |
| Sequel Med Tech, LLC | 2 | $56 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Averitas Pharma Inc. | 1 | $39 |
| Abbott | 2 | $38 |
| Viiv Healthcare Company | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Mannkind Corporation | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$3,450
- t-slim insulin pump$732
- Minimed 670G System$180
How this compares
$6,338 in reported general payments places this provider in the 75th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 204 | $241,349 |
| Tresiba Flextouch U-200Insulin Degludec | 71 | $116,014 |
| MounjaroTirzepatide | 85 | $98,662 |
| TrulicityDulaglutide | 77 | $89,666 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $48,652 |
| ProliaDenosumab | 27 | $45,235 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $42,871 |
| JardianceEmpagliflozin | 37 | $39,625 |
| JanuviaSitagliptin Phosphate | 45 | $36,810 |
| FarxigaDapagliflozin Propanediol | 37 | $30,265 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $28,006 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $26,614 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $21,244 |
| Novolog FlexpenInsulin Aspart | 72 | $19,945 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $16,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $280 | $256,834245 claims |
| AmgenProlia | $148 | $45,23527 claims |
| AstraZenecaFarxiga | $3,573 | $30,26537 claims |
| Sanofi-aventis U.S. LLCLantus | $40 | $3,75915 claims |
| AbbVieSynthroid | $75 | $3,41161 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $3,116480 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Columbia
- Michael GardnerColumbia$40K
- Sonya AddisonColumbia$25K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.